Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Novo Nordisk stock in Canada

Novo Nordisk stock has moved 0.81% from yesterday's closing price. Learn how to easily invest in Novo Nordisk stock.

Novo Nordisk is a biotechnology business based in the US. Novo Nordisk stocks (NVO.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $117.83 – an increase of 3.87% over the previous week. Novo Nordisk employs 52,696 staff and has a trailing 12-month revenue of around $167.2 billion.

How to buy Novo Nordisk stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – NVO. It's that simple.

Novo Nordisk stock price (NYSE:NVO)

Use our graph to track the performance of NVO stocks over time.

Novo Nordisk shares at a glance

Information last updated 2022-11-22.
Latest market close$117.83
52-week range$90.40 - $121.50
50-day moving average $106.36
200-day moving average $108.11
Wall St. target price$126.84
PE ratio 35.6563
Dividend yield $11.15 (1.41%)
Earnings per share (TTM) $3.23

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
min $1.00, max 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
FREE TRADES
National Bank Direct Brokerage
Finder Rating:
★★★★★
4.1 / 5
$0
$0 if conditions met, or $100
Stocks, Bonds, Options, Mutual Funds, GICs
$0 commission on all transactions for Finder investors.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
FREE TRADES
Wealthsimple
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $2,000 cashback + a $50 bonus on sign up. Use promo code CASHBONUS2023. Conditions apply. Ends March 1, 2023.
loading

Compare up to 4 providers

Is it a good time to buy Novo Nordisk stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Novo Nordisk price performance over time

Historical closes compared with the close of $117.83 from 2022-11-23

1 week (2022-11-18) 3.87%
1 month (2022-10-26) 9.29%
3 months (2022-08-26) 8.41%
6 months (2022-05-26) 10.53%
1 year (2021-11-26) 8.93%
2 years (2020-11-25) 78.15%
3 years (2019-11-26) 109.48%
5 years (2017-11-24) 125.56%

Is Novo Nordisk under- or over-valued?

Valuing Novo Nordisk stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Novo Nordisk's P/E ratio

Novo Nordisk's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 36x. In other words, Novo Nordisk shares trade at around 36x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Novo Nordisk's PEG ratio

Novo Nordisk's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7439. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Novo Nordisk's EBITDA

Novo Nordisk's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $77.6 billion.

The EBITDA is a measure of a Novo Nordisk's overall financial performance and is widely used to measure a its profitability.

Novo Nordisk financials

Revenue TTM $167.2 billion
Operating margin TTM 43.1%
Gross profit TTM $117.1 billion
Return on assets TTM 21.6%
Return on equity TTM 73.99%
Profit margin 31.6%
Book value $33.91
Market capitalisation $259.4 billion

TTM: trailing 12 months

Novo Nordisk share dividends

7%

Dividend payout ratio: 6.9% of net profits

Recently Novo Nordisk has paid out, on average, around 6.9% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.41% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk shareholders could enjoy a 1.41% return on their shares, in the form of dividend payments. In Novo Nordisk's case, that would currently equate to about $11.15 per share.

While Novo Nordisk's payout ratio might seem low, this can signify that Novo Nordisk is investing more in its future growth.

Novo Nordisk's most recent dividend payout was on 23 August 2022. The latest dividend was paid out to all shareholders who bought their shares by 12 August 2022 (the "ex-dividend date").

Have Novo Nordisk's shares ever split?

Novo Nordisk's shares were split on a 5:1 basis on 9 January 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Novo Nordisk shares which in turn could have impacted Novo Nordisk's share price.

Novo Nordisk share price volatility

Over the last 12 months, Novo Nordisk's shares have ranged in value from as little as $90.4 up to $121.5047. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk's is 0.3235. This would suggest that Novo Nordisk's shares are less volatile than average (for this exchange).

Novo Nordisk overview

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site